BCL2 and cancer: However, if cancer cells have already reached some degree of resistance, the inhibition of mTOR can also generate JNK activation, P-ERK upregulation, and Bcl-2/Bcl-xL phosphorylation in the breast, gastric and esophageal cancer, with subsequent activation of protective autophagy (203–205).